Latest Immunotherapy Treatments
A new immunotherapy treatment is showing promising results against mesothelioma. The therapy consists of a combination of two drugs: one drug that reprograms macrophages and the other is the chemotherapy cisplatin. Mesothelioma is a cancer that does not respond well to treatment. The best option for patients is a combination of surgery, chemotherapy, and radiation,…
Researchers have found a treatment that can eradicate advanced stage mesothelioma tumors within a few days. The research is being done at Rice University and Baylor College of Medicine. The treatment utilizes implants known as “drug factories” and a checkpoint inhibitor drug. Mesothelioma is a tough to treat cancer of the mesothelium, which is a…
A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in Vienna, Austria. The two drugs…
Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite Systemic Therapy. Researchers in the…
Promising results from a study on pleural mesothelioma were recently released. The study found when patients were treated with a new combination treatment, patients lived longer and had a better quality of life. The phase I clinical trial utilized a targeted cancer vaccine known as galinpepimut-S (GPS) and the immunotherapy drug Opdivo. SELLAS Life Sciences…
Targeted research is advancing the treatment of pleural mesothelioma. Results from a study on a novel protein inhibitor known as tazemetostat (brand name Tazverik) were recently released. It is showing impressive results as a second line treatment for mesothelioma patients with the BAP1 genetic mutation. The control rate for disease was 54.1 percent at 12…
The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by Xencor, a pharmaceutical company located…
A phase II clinical trial comparing anetumab ravtansine to the chemotherapy drug vinorelbine did not have promising results for treating mesothelioma like researchers had hoped. Anetumab ravtansine is an immunotherapy drug that is a monoclonal antibody, which is an engineered antibody that can be used to fight cancer. Researchers found that anetumab ravtansine did not…
Researchers are looking at a vaccine to maintain patient health after cancer treatment, which could be effective for mesothelioma in the future. The vaccine is specifically made for each patient based on the individual’s biology. The trial is currently being tested on head and neck cancer. It does not usually take long for mesothelioma to…
Researchers are looking at a new treatment for mesothelioma. It is a multimodal treatment (multiple treatments combined) consisting of the immunotherapy drug Keytruda and a new drug called OT-101. OT-101 is an antisense drug, which is a drug that blocks molecules that make certain proteins. The drug is also effective at treating COVID-19. It blocks…
